Intrexon Corporation Press Releases

XON 
$20.71
*  
0.05
0.24%
Get XON Alerts
*Delayed - data as of Aug. 27, 2014  -  Find a broker to begin trading XON now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Fibrocell Science, Inc. to Move Stock Listing to NASDAQ
8/18/2014 4:05:00 PM - Business Wire

Intrexon Announces Second Quarter and First Half 2014 Financial Results
8/14/2014 4:30:00 PM - PR Newswire

Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
8/14/2014 6:58:00 AM - PR Newswire

Intrexon to Announce First Half and Second Quarter 2014 Results and Host Conference Call on August 14th
8/12/2014 8:30:00 AM - PR Newswire

Intrexon Launches Leadership Platform in Bovine Genetics
8/11/2014 8:30:00 AM - PR Newswire

Fibrocell Science Reports Second Quarter and First Half 2014 Financial and Operating Results
8/11/2014 8:00:00 AM - Business Wire

Soligenix Reports Second Quarter 2014 Financial Results, and Highlights Recent Accomplishments
8/11/2014 7:30:00 AM - PR Newswire

Soligenix Advances Development of a Heat Stable Rapidly Acting Anthrax Vaccine VeloThrax™
8/7/2014 7:00:00 AM - PR Newswire

Fibrocell Science to Present at Wedbush 2014 Life Sciences Management Access Conference
8/5/2014 4:05:00 PM - Business Wire

Fibrocell Science to Report Second Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on August 11, 2014
8/4/2014 4:05:00 PM - Business Wire

Intrexon to Present at Jefferies 2014 Global Industrials Conference
8/4/2014 8:30:00 AM - PR Newswire

Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield™ in GI ARS
8/1/2014 7:30:00 AM - PR Newswire

Intrexon Enters into Technology Collaboration to Advance Animal Health Applications
7/29/2014 8:30:00 AM - PR Newswire

Fibrocell Science Takes Active Role to Support Dystrophic Epidermolysis Bullosa Patient Advocacy Group
7/23/2014 8:05:00 AM - Business Wire

ZIOPHARM Announces Expansion of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon and Clinical Program Update
7/22/2014 7:00:00 AM - GlobeNewswire

Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference
7/21/2014 6:58:00 AM - PR Newswire

Soligenix Announces Combination Vaccine for Ricin and Anthrax Achieves Simultaneous Protection
7/9/2014 7:00:00 AM - PR Newswire

Intrexon to Acquire Trans Ova Genetics
7/1/2014 4:46:00 PM - PR Newswire

Intrexon's Industrial Products Division Achieves Bioconversion of Methane to Farnesene
6/30/2014 8:30:00 AM - PR Newswire

FIbrocell Science Announces Exclusive Technology License Agreements with UCLA to Advance the Development of Personalized Cell Therapies
6/17/2014 8:00:00 AM - Business Wire

Fibrocell Science Receives Orphan Drug Designation for Genetically-Modified Autologous Human Fibroblasts to Advance Treatment Development for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
6/13/2014 8:00:00 AM - Business Wire

Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price Target
6/11/2014 9:00:00 AM - Market Wire